The Swedish Health Agency on Tuesday suggested that individuals under 65 years of age who got the originally shot of the AstraZeneca Covid antibody ought to get an alternate immunization for the subsequent shot.
Why it is important: There are no conclusive examinations with respect to resistant reactions when starting and follow-up immunization dosages are unique. The organization said that when results on blending various dosages are delivered they will assess whether the proposal ought to be changed.
Researchers from the University of Oxford in February began a trial where people received a dose of the Pfizer-BioNTech vaccine after a dose of AstraZeneca’s or vice versa, per the New York Times. They will analyze the participants’ blood to see how they respond to the mixing.
What they’re saying: “The recommendation that people under the age of 65 should not be vaccinated with AstraZeneca’s vaccine Vaxzevria remains for the time being,” the agency said
“People under the age of 65 who have already received a dose of Vaxzevria should instead be offered a second dose of so-called mRNA vaccine, such as Pfizer-BioNTech or Moderna.”
The agency is recommending that those who received their first AstraZeneca dose should receive a second dose of an mRNA vaccine approximately 12–15 weeks after, and no additional booster mRNA dose is required.
For people over 65, the benefits of the AstraZeneca vaccine outweigh the risks.